Literature DB >> 17886125

Tularaemia in an emergent area in Sweden: an analysis of 234 cases in five years.

Henrik Eliasson1, Erik Bäck.   

Abstract

A retrospective study of clinical tularaemia in an emergent area in Sweden is presented. 234 patients seen during the y 2000-2004 were studied, using case files and a questionnaire. There was a predominance of ulceroglandular tularaemia (89%), occurring in late summer and early autumn, reflecting the dominance of mosquito-borne transmission. The incubation period varied from a few hours to 11 d, with a median of 3 d. Cutaneous manifestations of tularaemia, apart from primary lesions, were noted in 43% of the cases. Coughing was common, even in patients with ulceroglandular tularaemia, supporting the view that haematogenous spread to the respiratory system occurs. Regular laboratory tests, such as WBC, ESR and C-reactive protein, were in general only moderately elevated. In the earlier y studied, the Doctor's Delay was substantial as was the misdiagnosis and prescription of inadequate antibiotics. In the later y, however, the delay and misdiagnosis were significantly lower, reflecting the increased recognition of the disease by the physicians in the area. A few relapses occurred, all in patients treated with doxycycline. No lethality was seen, reflecting the benign course of tularaemia type B infection.

Entities:  

Mesh:

Year:  2007        PMID: 17886125     DOI: 10.1080/00365540701402970

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  33 in total

1.  Kinetics of the immune response associated with tularemia: comparison of an enzyme-linked immunosorbent assay, a tube agglutination test, and a novel whole-blood lymphocyte stimulation test.

Authors:  Henrik Eliasson; Per Olcén; Anders Sjöstedt; Margareta Jurstrand; Erik Bäck; Sören Andersson
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

2.  OpiA, a Type Six Secretion System Substrate, Localizes to the Cell Pole and Plays a Role in Bacterial Growth and Viability in Francisella tularensis LVS.

Authors:  Stuart Cantlay; Kristen Haggerty; Joseph Horzempa
Journal:  J Bacteriol       Date:  2020-06-25       Impact factor: 3.490

3.  Enhanced survival but not amplification of Francisella spp. in the presence of free-living amoebae.

Authors:  Helen Y Buse; Frank W Schaefer; Eugene W Rice
Journal:  Acta Microbiol Immunol Hung       Date:  2016-12-08       Impact factor: 2.048

4.  [Tularemia lymphadenitis. An emerging differential diagnosis of necrotizing granulomatous cervical lymphadenitis].

Authors:  J Strehl; C Schoerner; A Hartmann; A Agaimy
Journal:  Pathologe       Date:  2014-03       Impact factor: 1.011

Review 5.  Ecology of Francisella tularensis.

Authors:  Sam R Telford; Heidi K Goethert
Journal:  Annu Rev Entomol       Date:  2019-10-10       Impact factor: 19.686

6.  Structure and function of REP34 implicates carboxypeptidase activity in Francisella tularensis host cell invasion.

Authors:  Geoffrey K Feld; Sahar El-Etr; Michele H Corzett; Mark S Hunter; Kamila Belhocine; Denise M Monack; Matthias Frank; Brent W Segelke; Amy Rasley
Journal:  J Biol Chem       Date:  2014-09-17       Impact factor: 5.157

7.  An unexpected cause for cavitary pneumonia and empyema.

Authors:  Constantine Bloch-Infanger; Katarzyna Furrer; Mark Wiese; Andreas Hiebinger; Christoph M Bucher; Sébastien Kopp; Vladimira Hinić; Daniel Goldenberger
Journal:  Infection       Date:  2015-11-30       Impact factor: 3.553

8.  [Fever and lymphadenopathy. Report of 4 cases of tularemia].

Authors:  C Bloch; A Friedl; F Zucol; A Widmer; N Khanna
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

9.  Tularemia in children.

Authors:  Solmaz Celebi; Mustafa Hacimustafaoglu; Suna Gedikoglu
Journal:  Indian J Pediatr       Date:  2008-09-22       Impact factor: 1.967

10.  Francisella novicida forms in vitro biofilms mediated by an orphan response regulator.

Authors:  Meghan W Durham-Colleran; Anne Brooks Verhoeven; Monique L van Hoek
Journal:  Microb Ecol       Date:  2009-09-19       Impact factor: 4.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.